Global Search | Novartis

Hide Filters

Sort by

Relevance

Newest first

Oldest first

Showing 1213 results

Media Release / Sep 29, 2021
Novartis and Medicines for Malaria Venture report positive results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malaria
Novartis and Medicines for Malaria Venture (MMV) report positive Phase 2b study results for novel non-artemisinin combination to treat uncomplicated malariaIn the Phase 2b study conducted in children…
Media Release / Sep 29, 2021
New data reinforce efficacy and convenience of Novartis Cosentyx® (secukinumab) 300 mg autoinjector in adults with psoriasis
New findings show Cosentyx® (secukinumab) 300 mg single dose autoinjector (the UnoReady® pen) resulted in superior efficacy vs placebo1 Patient satisfaction with 300 mg autoinjector…
Media Release / Sep 29, 2021
Novartis data show achieving complete control of chronic spontaneous urticaria (CSU) improves overall quality of life, as reported by patients
Data analysis shows that preventing the symptoms of CSU (achieving complete control) improves overall health-related quality of life (HRQoL); including sleep and work productivity, among other…
Media Release / Sep 21, 2021
Novartis acquires Arctos Medical, expanding optogenetics portfolio to bring gene therapies to patients with severe vision loss
Acquisition underscores Novartis commitment to using optogenetics-based therapies to restore vision to patients with advanced blindness Novartis gains one pre-clinical optogenetic AAV gene therapy…
Media Release / Sep 21, 2021
Novartis acquiert Arctos Medical, élargissant ainsi son portefeuille d’optogénétique afin de proposer des thérapies géniques aux patients souffrant d’une sévère perte de la vision
Cette acquisition souligne l’engagement de Novartis à utiliser des thérapies basées sur l’optogénétique pour redonner la vue aux patients atteints de cécité avancéeNovartis acquiert un programme…
Media Release / Sep 21, 2021
Novartis übernimmt Arctos Medical und erweitert damit ihr Optogenetik-Portfolio, um Patientinnen und Patienten mit einem schwerem Verlust des Sehvermögens Gentherapien anbieten zu können
Mit der Übernahme unterstreicht Novartis ihre Absicht, das Sehvermögen von Patientinnen und Patienten mit einem fortgeschrittenen Sehverlust mittels Optogenetik wiederherzustellenNovartis sichert…
Media Release / Sep 19, 2021
Novartis announces collaboration on HARMONIA, a Phase III, head-to-head trial evaluating Kisqali® vs. Ibrance®* in patients with HR+/HER2- advanced breast cancer
HARMONIA seeks to identify the best therapeutic option between Kisqali and Ibrance® for patients with aggressive HER2-enriched intrinsic subtype of HR+/HER2- advanced breast cancer (ABC)…
Media Release / Sep 19, 2021
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced…
Media Release / Sep 17, 2021
Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)
PROS is a spectrum of rare disorders caused by PIK3CA mutations and is characterized by atypical, visible overgrowths and anomalies in blood vessels, the lymphatic system and other tissuesAt 24 weeks…
Media Release / Sep 17, 2021
Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021
New quality of life data for 177Lu-PSMA-617 plus standard of care shows delay in worsening of health-related quality of life (HRQoL) and pain in heavily pre-treated patients with PSMA-positive…

‹ Previous page
1
…
25
26
27
28
29
30
31
…
122
› Next page